Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

High-Dose Vitamin C Preadministration Reduces Vancomycin-Associated Nephrotoxicity in Mice.

Takigawa M, Yatsu T, Takino Y, Matsumoto S, Kitano T, Lee J, Arai T, Tanaka H, Ishii T, Mori Y, Ishigami A.

J Nutr Sci Vitaminol (Tokyo). 2019;65(5):399-404. doi: 10.3177/jnsv.65.399.

2.

Kinetics and Mechanism of Intramolecular Electron Transfer in Ru(II)-Re(I) Supramolecular CO2-Reduction Photocatalysts: Effects of Bridging Ligands.

Yamazaki Y, Ohkubo K, Saito D, Yatsu T, Tamaki Y, Tanaka S, Koike K, Onda K, Ishitani O.

Inorg Chem. 2019 Sep 3;58(17):11480-11492. doi: 10.1021/acs.inorgchem.9b01256. Epub 2019 Aug 16.

PMID:
31418554
3.

Vitamin C deficiency causes muscle atrophy and a deterioration in physical performance.

Takisawa S, Funakoshi T, Yatsu T, Nagata K, Aigaki T, Machida S, Ishigami A.

Sci Rep. 2019 Mar 20;9(1):4702. doi: 10.1038/s41598-019-41229-7.

4.

Electrocatalytic reduction of low concentration CO2.

Kumagai H, Nishikawa T, Koizumi H, Yatsu T, Sahara G, Yamazaki Y, Tamaki Y, Ishitani O.

Chem Sci. 2018 Nov 12;10(6):1597-1606. doi: 10.1039/c8sc04124e. eCollection 2019 Feb 14.

5.

Synthesis of 6-Amino- and 6-Arylazoazulenes via Nucleophilic Aromatic Substitution and Their Reactivity and Properties.

Shoji T, Sugiyama S, Takeuchi M, Ohta A, Sekiguchi R, Ito S, Yatsu T, Okujima T, Yasunami M.

J Org Chem. 2019 Feb 1;84(3):1257-1275. doi: 10.1021/acs.joc.8b02648. Epub 2019 Jan 15.

PMID:
30620591
6.

Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells.

Yatsu T, Kusakabe T, Kato K, Inouye Y, Nemoto K, Kanno Y.

Biol Pharm Bull. 2018;41(3):394-398. doi: 10.1248/bpb.b17-00748.

7.

Observed adducts on positive mode direct analysis in real time mass spectrometry - Proton/ammonium adduct selectivities of 600-sample in-house chemical library.

Sugimura N, Furuya A, Yatsu T, Igarashi Y, Aoyama R, Izutani C, Yamamoto Y, Shibue T.

Eur J Mass Spectrom (Chichester). 2017 Feb;23(1):4-10. doi: 10.1177/1469066717693851. Epub 2017 Jan 1.

PMID:
28657446
8.

Alisol B 23-acetate from the rhizomes of Alisma orientale is a natural agonist of the human pregnane X receptor.

Kanno Y, Yatsu T, Yamashita N, Zhao S, Li W, Imai M, Kashima M, Inouye Y, Nemoto K, Koike K.

Phytomedicine. 2017 Mar 15;26:22-27. doi: 10.1016/j.phymed.2017.01.003. Epub 2017 Jan 9.

PMID:
28257661
9.

Palladium(II) Catalyzed Cyclization-Carbonylation-Cyclization Coupling Reaction of (ortho-Alkynyl Phenyl) (Methoxymethyl) Sulfides Using Molecular Oxygen as the Terminal Oxidant.

Shen R, Kusakabe T, Yatsu T, Kanno Y, Takahashi K, Nemoto K, Kato K.

Molecules. 2016 Sep 5;21(9). pii: E1177. doi: 10.3390/molecules21091177.

10.

Prediction of adducts on positive mode electrospray ionization mass spectrometry: proton/sodium selectivity in methanol solutions.

Sugimura N, Furuya A, Yatsu T, Shibue T.

Eur J Mass Spectrom (Chichester). 2015;21(5):725-31. doi: 10.1255/ejms.1389.

PMID:
26579928
11.

Comparison of the applicability of mass spectrometer ion sources using a polarity- molecular weight scattergram with a 600 sample in-house chemical library.

Sugimura N, Furuya A, Yatsu T, Shibue T.

Eur J Mass Spectrom (Chichester). 2015;21(2):91-6. doi: 10.1255/ejms.1345.

PMID:
26181282
12.

Nigramide J is a novel potent inverse agonist of the human constitutive androstane receptor.

Kanno Y, Tanuma N, Yatsu T, Li W, Koike K, Inouye Y.

Pharmacol Res Perspect. 2014 Feb;2(1):2. doi: 10.1002/prp2.18. Epub 2014 Jan 26.

13.

Nigramide C is a natural agonist of human pregnane x receptor.

Kanno Y, Yatsu T, Li W, Koike K, Inouye Y.

Drug Metab Dispos. 2014 Jun;42(6):1084-9. doi: 10.1124/dmd.114.057810. Epub 2014 Apr 4.

PMID:
24705672
14.

Effects of high glucose on AVP-induced hyperplasia, hypertrophy, and type IV collagen synthesis in cultured rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Endocr Res. 2012;37(4):216-27. doi: 10.3109/07435800.2012.671400. Epub 2012 May 17.

PMID:
22594926
15.

Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Clin Exp Pharmacol Physiol. 2012 May;39(5):438-46. doi: 10.1111/j.1440-1681.2012.05693.x.

PMID:
22352691
16.

Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

J Physiol Sci. 2011 Mar;61(2):115-22. doi: 10.1007/s12576-010-0128-5. Epub 2011 Jan 13.

PMID:
21229342
17.

Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Neuropeptides. 2011 Apr;45(2):105-11. doi: 10.1016/j.npep.2010.12.001. Epub 2010 Dec 31.

PMID:
21196048
18.

Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes.

Tsukamoto I, Koshio H, Orita M, Saitoh C, Yanai-Inamura H, Kitada-Nozawa C, Yamamoto E, Yatsu T, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2009 Dec 15;17(24):8161-7. doi: 10.1016/j.bmc.2009.10.038. Epub 2009 Oct 23.

PMID:
19900813
19.

Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.

Tsukamoto I, Koshio H, Kuramochi T, Saitoh C, Yanai-Inamura H, Kitada-Nozawa C, Yamamoto E, Yatsu T, Shimada Y, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2009 Apr 15;17(8):3130-41. doi: 10.1016/j.bmc.2009.03.001. Epub 2009 Mar 9.

PMID:
19321349
20.

Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.

Tsukamoto I, Koshio H, Akamatsu S, Kuramochi T, Saitoh C, Yatsu T, Yanai-Inamura H, Kitada C, Yamamoto E, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2008 Nov 1;16(21):9524-35. doi: 10.1016/j.bmc.2008.09.039. Epub 2008 Sep 17.

PMID:
18835174
21.

9-Deazaguanine derivatives: synthesis and inhibitory properties as multi-substrate analogue inhibitors of mammalian PNPs.

Yatsu T, Hashimoto M, Hikishima S, Magnowska L, Bzowska A, Yokomatsu T.

Nucleic Acids Symp Ser (Oxf). 2008;(52):661-2. doi: 10.1093/nass/nrn334.

PMID:
18776553
22.

Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Pharmacol Res. 2008 Feb;57(2):142-50. doi: 10.1016/j.phrs.2008.01.003. Epub 2008 Jan 20.

PMID:
18299204
23.

Effect of vasopressin on type IV collagen production in human mesangial cells.

Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M.

Regul Pept. 2008 Apr 10;147(1-3):60-6. doi: 10.1016/j.regpep.2008.01.002. Epub 2008 Jan 7.

PMID:
18258315
24.

Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M.

Clin Exp Pharmacol Physiol. 2008 May;35(5-6):586-93. doi: 10.1111/j.1440-1681.2007.04852.x. Epub 2007 Dec 27.

PMID:
18177476
25.

Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.

Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M.

Vascul Pharmacol. 2007 Jun;46(6):463-9. Epub 2007 Mar 1.

PMID:
17395547
26.

Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Kusayama T, Momose K, Taniguchi N, Suzuki T, Yatsu T, Shibasaki M.

Pharmacology. 2006;78(2):81-90. Epub 2006 Sep 11.

PMID:
16966841
27.

Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.

Tahara A, Tsukada J, Tomura Y, Momose K, Suzuki T, Yatsu T, Shibasaki M.

Eur J Pharmacol. 2006 May 24;538(1-3):32-8. Epub 2006 Apr 1.

PMID:
16678155
28.

Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.

Shimada Y, Taniguchi N, Matsuhisa A, Akane H, Kawano N, Suzuki T, Tobe T, Kakefuda A, Yatsu T, Tahara A, Tomura Y, Kusayama T, Wada K, Tsukada J, Orita M, Tsunoda T, Tanaka A.

Bioorg Med Chem. 2006 Mar 15;14(6):1827-37. Epub 2005 Nov 11.

PMID:
16290163
29.

Iris-derived cells from adult rodents and primates adopt photoreceptor-specific phenotypes.

Akagi T, Akita J, Haruta M, Suzuki T, Honda Y, Inoue T, Yoshiura S, Kageyama R, Yatsu T, Yamada M, Takahashi M.

Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3411-9.

PMID:
16123446
30.

Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.

Shimada Y, Akane H, Taniguchi N, Matsuhisa A, Kawano N, Kikuchi K, Yatsu T, Tahara A, Tomura Y, Kusayama T, Wada K, Tsukada J, Tsunoda T, Tanaka A.

Chem Pharm Bull (Tokyo). 2005 Jul;53(7):764-9.

31.

Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats.

Yatsu T, Aoki M, Tanaka A.

Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6.

PMID:
15740732
32.

Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.

Tsukada J, Tahara A, Tomura Y, Kusayama T, Wada K, Ishii N, Taniguchi N, Suzuki T, Yatsu T, Uchida W, Shibasaki M.

Vascul Pharmacol. 2005 Jan;42(2):47-55.

PMID:
15722249
33.

Comparison between YM099 and captopril in rats with renal mass reduction-induced progressive renal disease.

Yatsu T, Aoki M, Uchida W, Inagaki O.

Biol Pharm Bull. 2005 Feb;28(2):367-9.

34.

Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.

Tahara A, Tsukada J, Tomura Y, Kusayama T, Wada K, Ishii N, Taniguchi N, Suzuki T, Yatsu T, Uchida W, Shibasaki M.

Pharmacol Res. 2005 Mar;51(3):275-81.

PMID:
15661579
35.

Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.

Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, Sasamata M, Miyata K.

Eur J Pharmacol. 2005 Jan 10;507(1-3):145-51. Epub 2005 Jan 1.

PMID:
15659304
36.

The differential role of exogenous and endogenous prostacyclin in the control of renin release from dog renal cortical slices.

Yatsu T, Kurosawa H, Satoh H, Hayashi M, Satoh S.

J Cardiovasc Pharmacol. 2004 Dec;44(6):676-81.

PMID:
15550787
37.

Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.

Shimada Y, Taniguchi N, Matsuhisa A, Yatsu T, Tahara A, Tanaka A.

Chem Pharm Bull (Tokyo). 2003 Sep;51(9):1075-80.

38.

Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction.

Yatsu T, Sanagi M, Fujimori A, Tomura Y, Hayashi K, Tanahashi M, Inagaki O.

Pharmacol Res. 2003 Mar;47(3):243-52.

PMID:
12591020
39.

Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats.

Yatsu T, Aoki M, Inagaki O.

Eur J Pharmacol. 2003 Feb 14;461(2-3):191-5.

PMID:
12586214
40.

Alterations of renal vasopressin V1A and V2 receptors in spontaneously hypertensive rats.

Tahara A, Tsukada J, Tomura Y, Wada K, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Pharmacology. 2003 Feb;67(2):106-12.

PMID:
12566855
41.

The role of Ca2+ in the control of renin release from dog renal cortical slices.

Yatsu T, Kurosawa H, Hayashi M, Satoh S.

Eur J Pharmacol. 2003 Jan 1;458(1-2):191-6.

PMID:
12498925
42.

Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs.

Yatsu T, Kusayama T, Tomura Y, Arai Y, Aoki M, Tahara A, Wada K, Tsukada J.

Pharmacol Res. 2002 Nov;46(5):375-81.

PMID:
12419640
43.

Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells.

Tahara A, Tsukada J, Tomura Y, Wada K, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Peptides. 2002 Oct;23(10):1809-16.

PMID:
12383869
44.

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.

Wada K, Tahara A, Arai Y, Aoki M, Tomura Y, Tsukada J, Yatsu T.

Eur J Pharmacol. 2002 Aug 23;450(2):169-77.

PMID:
12206855
45.

Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells.

Tahara A, Tsukada J, Tomura Y, Kusayama T, Wada K, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

J Hypertens. 2002 Sep;20(9):1807-14.

PMID:
12195123
46.

Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.

Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Aoki M, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Eur J Pharmacol. 2002 Jun 20;446(1-3):129-38.

PMID:
12098594
47.

Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.

Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Br J Pharmacol. 2001 Jul;133(5):746-54.

48.

Norepinephrine release is increased in the hibernating heart, studied in a chronic canine model of myocardial hibernation.

Ohtsuka S, Suzuki S, Ishikawa K, Uchida W, Yatsu T, Yamaguchi I.

J Cardiovasc Pharmacol. 2000;36 Suppl 2:S35-41.

PMID:
11206718

Supplemental Content

Support Center